23:39:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo.


2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-22 07:00:00
Lytix Biopharma AS will release its third quarter 2021 results on Thursday, 25
November 2021 at 07.00 a.m. CEST. The results will be presented in a webcast
with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 14.30

The presentation and subsequent Q&A session will be held in English and may be
viewed live at https://forms.office.com/r/7FV1WJGZgJ

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/overview.html after the presentation.

For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company
developing novel cancer immunotherapies, an area within cancer therapy that is
aimed at activating the patient's immune system to fight cancer. The Company's
technology is based on pioneering research in "host defense peptides" - nature's
first line of defense towards foreign pathogens. Lytix Biopharma's lead product,
LTX-315, is a first-in-class oncolytic molecule representing a new and superior
in situ therapeutic vaccination principle to boost anti-cancer immunity, with
the potential to be the ideal combination partner with other types of
immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells.